Drug of Abuse Testing Market Report 2026

The drug of abuse testing market size has grown strongly in recent years. It will grow from $7.16 billion in 2025 to $7.64 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to manual laboratory confirmation methods dependency, expansion of workplace drug screening regulations, growth of forensic toxicology laboratories, introduction of immunoassay testing techniques, increasing opioid crisis awareness programs.

The drug of abuse testing market size is expected to see strong growth in the next few years. It will grow to $9.97 billion by 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising substance abuse monitoring initiatives, expansion of mandatory workplace testing policies, increased adoption of rapid point of care testing kits, growing forensic and criminal investigation demand, expansion of global rehabilitation and treatment programs. Major trends in the forecast period include Point of care rapid drug screening adoption, workplace drug testing compliance expansion, forensic toxicology laboratory specialization growth, sports and athletic anti-doping testing programs, emergency department toxicology screening protocols.

The rising prevalence of substance abuse and addiction is anticipated to propel the growth of the drug of abuse testing market coming years. Substance abuse and addiction refer to the harmful or hazardous use of psychoactive substances, including illicit drugs and prescription medications, which can impair health, safety, and social or legal functioning. The prevalence of substance abuse and addiction is growing due to easier access to drugs and changing social behaviors that normalize or increase drug use. Drug of abuse testing helps address substance abuse and addiction by enabling early detection of drug use, guiding timely medical interventions, monitoring recovery progress, and supporting public health strategies to reduce the harmful impact of substance misuse. For instance, in December 2025, according to the Addiction Policy Forum, a US-based non-profit organization, Of the 48.4 million people with a substance use disorder, 27.9 million had an alcohol use disorder and 28.2 million had a drug use disorder in 2024. Therefore, the rising prevalence of substance abuse and addiction is driving the growth of the drug of abuse testing market.

Leading companies operating in the drug of abuse testing market are focusing on developing advanced products such as multi-analyte clinical drug testing panels to enable faster, more accurate, and comprehensive detection of multiple drugs simultaneously. Multi-analyte clinical drug testing panels are devices that simultaneously detect multiple drugs of abuse from a single sample, helping healthcare and forensic professionals quickly identify substance use with high accuracy and efficiency compared to traditional single-drug tests. For example, in February 2026, Randox USA, a U. S. -based diagnostics company, received 510(k) clearance from the U. S. Food and Drug Administration (FDA) for its Evidence MultiSTAT, an innovative multi-analyte clinical drug testing panel. The device is a fully automated, cartridge-based analyzer that uses patented Biochip Technology to simultaneously detect 15 drugs of abuse from urine in just 21 minutes. It features a simple three-step testing process, pre-filled reagent cartridges, and delivers results with high accuracy comparable to confirmatory laboratory methods. The Evidence MultiSTAT covers a wide range of drug classes, including opioids, fentanyl, methamphetamine, cocaine, benzodiazepines, and cannabinoids, making it suitable for use in hospital laboratories, emergency departments, pain management clinics, behavioral health centers, and forensic settings. This technology improves efficiency, reduces human error, and provides rapid, reliable results compared to traditional single-analyte tests.

In October 2025, Archimed Diagnostics, a France-based healthcare technology company, acquired Ark Diagnostics for an undisclosed value. Through this acquisition, Archimed Diagnostics seeks to strengthen its position in the in vitro diagnostics market by incorporating Ark’s expertise in rapid diagnostic testing, thereby expanding its product portfolio with innovative, high-performance solutions for infectious disease detection and point-of-care testing. Ark Diagnostics is a US-based healthcare technology company specializing in drugs of abuse (DoA) testing solutions.

Major companies operating in the drug of abuse testing market are F. Hoffmann‑La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Drägerwerk AG & Co. KGaA, Shimadzu Corporation, Bio‑Rad Laboratories Inc., OraSure Technologies, Clinical Reference Laboratory (CRL) Inc., Legacy Medical Services, Intoximeters Inc., Cordant Health Solutions, DrugScan, Premier Biotech Inc., UCP Biosciences, American Screening Corporation Inc., SureHire Inc.

North America was the dominating region in the drug of abuse testing market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the drug of abuse testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug of abuse testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug of abuse testing market includes revenues earned by entities by providing services such as laboratory testing, specimen collection, sample transportation, result interpretation, clinical consultation, workplace drug screening, forensic analysis, point-of-care testing, confirmatory testing, counseling and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.